Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma (OS2006)
OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant
Sponsor: Chugai Pharmaceutical
This PHASE3 trial investigates Sarcoma and is currently ongoing. Chugai Pharmaceutical leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Feb 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Terminated → Active Not Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chugai Pharmaceutical
- Ligue contre le cancer, France
- National Cancer Institute, France
- Novartis
- SFCE
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Besançon, France , Bordeaux, France , Brest, France , Caen, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France , Lille, France , Lyon, France and 13 more locations